Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

Cited In for PubMed (Select 15148277)

1.

Cardiac risk in the treatment of breast cancer: assessment and management.

Valachis A, Nilsson C.

Breast Cancer (Dove Med Press). 2015 Jan 16;7:21-35. doi: 10.2147/BCTT.S47227. eCollection 2015. Review.

2.

Cardiovascular toxicities from systemic breast cancer therapy.

Guo S, Wong S.

Front Oncol. 2014 Dec 4;4:346. doi: 10.3389/fonc.2014.00346. eCollection 2014. Review.

3.

The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.

Herman E, Knapton A, Zhang J, Estis J, Todd J, Lipshultz S.

Pharmacol Res Perspect. 2014 Feb;2(1):e00015. doi: 10.1002/prp2.15. Epub 2014 Mar 3.

4.

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Christenson ES, James T, Agrawal V, Park BH.

Clin Biochem. 2015 Mar;48(4-5):223-235. doi: 10.1016/j.clinbiochem.2014.10.013. Epub 2014 Nov 7. Review.

5.

Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.

Stachowiak P, Kornacewicz-Jach Z, Safranow K.

Arch Med Sci. 2014 Oct 27;10(5):1007-18. doi: 10.5114/aoms.2013.34987. Epub 2013 Apr 30.

6.

Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S.

Front Oncol. 2014 Oct 9;4:277. doi: 10.3389/fonc.2014.00277. eCollection 2014. Review.

7.

Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?

Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, Silverstein C, Means-Powell J, Paranjape SY, Lenihan D, Sawyer DB, Raj SR.

Ecancermedicalscience. 2014 Jul 17;8:446. doi: 10.3332/ecancer.2014.446. eCollection 2014.

8.

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.

Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.

J Am Coll Cardiol. 2014 Mar 4;63(8):809-16. doi: 10.1016/j.jacc.2013.10.061. Epub 2013 Nov 27.

9.

Chemotherapy-induced Cardiotoxicity.

Florescu M, Cinteza M, Vinereanu D.

Maedica (Buchar). 2013 Mar;8(1):59-67.

10.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG.

JACC Cardiovasc Imaging. 2013 Aug;6(8):877-85. doi: 10.1016/j.jcmg.2012.11.017. Epub 2013 May 1.

11.

Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized Study.

Jo SH, Kim LS, Kim SA, Kim HS, Han SJ, Park WJ, Choi YJ.

Korean Circ J. 2013 Mar;43(3):174-81. doi: 10.4070/kcj.2013.43.3.174. Epub 2013 Mar 31.

12.

Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance.

Carver JR, Szalda D, Ky B.

Semin Oncol. 2013 Apr;40(2):229-38. doi: 10.1053/j.seminoncol.2013.01.005.

13.

Cardiorespiratory fitness in breast cancer survivors.

Burnett D, Kluding P, Porter C, Fabian C, Klemp J.

Springerplus. 2013 Dec;2(1):68. doi: 10.1186/2193-1801-2-68. Epub 2013 Feb 25.

14.

Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.

Sheppard RJ, Berger J, Sebag IA.

Front Pharmacol. 2013 Mar 12;4:19. doi: 10.3389/fphar.2013.00019. eCollection 2013.

15.

Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort.

Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, Mayer I, Means-Powell J, Freehardt D, White B, Lenihan D, Sawyer DB.

J Card Fail. 2013 Jan;19(1):10-5. doi: 10.1016/j.cardfail.2012.11.006.

16.

Elevated troponin I and its prognostic significance in acute liver failure.

Audimooolam VK, McPhail MJ, Sherwood R, Willars C, Bernal W, Wendon JA, Auzinger G.

Crit Care. 2012 Nov 28;16(6):R228. doi: 10.1186/cc11883.

17.

Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.

Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY.

Am J Cardiol. 2012 Dec 1;110(11):1679-86. doi: 10.1016/j.amjcard.2012.07.040. Epub 2012 Aug 21.

18.

Noninvasive diagnosis of chemotherapy related cardiotoxicity.

Gillespie HS, McGann CJ, Wilson BD.

Curr Cardiol Rev. 2011 Nov;7(4):234-44. Review.

19.

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.

Volkova M, Russell R 3rd.

Curr Cardiol Rev. 2011 Nov;7(4):214-20. Review.

20.

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.

Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603. Epub 2012 Jun 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk